On September 2, Johnson & Johnson rose 3.05% in regular trading, trading near $279.65 per share, with turnover of $320 million. The rally was primarily driven by UBS significantly raising its price target on the stock from $280 to $320 while maintaining a Buy rating, implying approximately 14% upside from the current level.

According to FactSet data, analysts hold an average Overweight rating on Johnson & Johnson with a mean price target of $279.71. Multiple firms including Guggenheim, Argus Research, and Wells Fargo have also recently raised their price targets, reflecting a broad wave of bullish sentiment toward the company.

The upgrade comes amid a series of positive catalysts. The FDA recently approved Imaavy as the first-ever treatment for warm autoimmune hemolytic anemia, while Rybrevant Faspro secured FDA priority review for head and neck cancer. The European Commission also approved Johnson & Johnson's Tecvayli plus daratumumab combination for multiple myeloma. Additionally, the company announced strategic agreements with Sail Biomedicines, including a $2.58 billion acquisition option to advance in vivo CAR-T therapies.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)